Who was studied, and how
One number in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 9 other studies
4,289people with type 2 diabetes, in this paper
The trial randomly assignedassigned by chance
canagliflozin
placebo
Raised drop in eGFR over 10%3×
randomisedthe abstract, start to end
… compared to placebo was significant at 3.03 (95% confidence interval 2.65, …
← favours treatmentfavours comparator →
could be chanceDrop in eGFR over 10%canagliflozin vs placebo
OR 3.032.65–3.47
SGLT2 inhibitorsKidney outcomes
SGLT2 inhibitors × kidney outcomeshelps?settled
unlikelylikely
0.890.88 without it
← favours comparatorfavours treatment →
1 / 6